The universal cyclin-dependent kinase inhibitor p27
translocations or through mutations in pathways that normally restrict Myc expression (22) . Expression of Myc at levels found in cancer cells is sufficient to drive primary quiescent cells into S phase (23) , to accelerate rates of cell proliferation (24) , and to prevent withdrawal from the cell cycle (25, 26) . However, these aberrant proliferative responses are harnessed by apoptotic checkpoints that are induced by Myc, including the Arf-p53 tumor suppressor pathway (27, 28) and the Bcl2 family of apoptotic regulators (28) . Accordingly, mutations that inactivate these apoptotic checkpoints are found in most tumors induced by Myc (28, 29) .
Myc accelerates the rates of cell proliferation, at least in part, through its ability to downregulate the expression of the Cdk inhibitor p27
Kip1 (30, 31) , which inactivates cyclin E-Cdk2 and cyclin A-Cdk2 complexes that orchestrate entry and progression through S phase (1, 6, 32) .
Myc suppresses p27
Kip1 expression at the level of transcription (33) , but its effects on p27 Kip1 protein levels in vivo are more profound (31) . First, Myc induces the expression of E2f1 (34) , which then promotes cyclin E transcription (35) , thus activating cyclin E-Cdk2 complexes (30) . Moreover, Myc induces the transcription of both cyclin D2 and its catalytic partner Cdk4, and this holoenzyme sequesters p27 Kip1 , thus relieving inhibition of cyclin E-Cdk2 complexes (36, 37) . Under either scenario, activated cyclin E-Cdk2 complexes then phosphorylate p27 Kip1 on Thr 187 , allowing its recognition by the SCF Skp2 complex, ubiquitination, and degradation by the proteasome (8, 9, 38) . Finally, Myc induces the expression of some of the components of the SCF Skp2 complex, including Cul1 (39) and Cks1, and at least the latter is required for downregulation of p27
Kip1 (31) . p27
Kip1 is a key regulator of Myc-induced proliferation and tumorigenesis. First, loss of p27
Kip1 accelerates lymphoma development in Eμ-Myc transgenic mice (40) , a mouse model of human Burkitt lymphoma (41) . Further, loss or heterozygosity of E2f1, or loss of Cks1, effectively cancels the ability of Myc to suppress p27
Kip1 protein (but not p27
Kip1 mRNA) levels, impairs Myc-induced proliferation, and markedly delays lymphoma onset and triples the life span of Eμ-Myc mice (31, 34) . Here, we report that Myc also induces the expression of the Skp2 F-box component of the SCF Skp2 complex in B cells and fibroblasts and that Skp2 is expressed at high levels in Myc-driven lymphomas of mice and man. As expected, Skp2 loss abolishes the suppression of p27
Kip1 protein in Eμ-Myc B cells. However, quite surprisingly, the effects of the Skp2 deficiency on Myc-induced proliferation and tumorigenesis are at most modest, suggesting that Cks1 has targets, in addition to p27 Kip1 , that contribute to lymphomagenesis.
Materials and Methods

Mice and Tumor Analysis
Skp2-null mice (C57BL/6; ref. −/− littermates. With institutional review board approval, and following informed consent, tumors from 14 Burkitt lymphoma patients were banked. RNA and protein were extracted from these tumors. As a control, pooled peripheral blood mononuclear cells from healthy donors were enriched using CD19 microbeads according to the manufacturer's instruction (Miltenyi Biotech), and RNA and protein were prepared.
Cell Culture
Primary bone marrow-derived pre-B cells were cultured as described previously (29) . Mouse embryo fibroblasts (MEF) from E13.5 to E14.5 embryos were cultured and infected with MSCV-Myc-ER TAM -IRES-GFP, MSCV-Myc-IRES-GFP, pBabe-Myc-ER TAM -IRESpuromycin, pBabe-ER TAM -E2f1-puromycin, or control retrovirus as described (27) . To evaluate consequences of Myc activation, cells were treated with 2 μmol/L 4-hydroxytamoxifen (4-HT) and harvested for protein and RNA preparation. To assess whether Myc induction of Skp2 was direct, Myc-ER-expressing cells or control cells were pretreated with 1 μg/mL cycloheximide (Sigma Chemicals) for 30 min (which inhibited >95% of protein synthesis) before adding 4-HT. For analysis of Skp2 RNA half-life, MEFs were cultured in the presence of 1 μg/mL actinomycin D (Sigma-Aldrich) and harvested at the indicated time. To estimate Skp2 protein half-life, MEFs were cultured in the presence of 10 μg/mL cycloheximide and harvested at the indicated time.
Fluorescence-Activated Cell Sorting Analysis and Magnetic-Activated Cell Sorting of B Cells
Rates of proliferation or apoptosis of B cells were determined using a Flow kit as described by the manufacturer (BD Biosciences Pharmingen). Bone marrow and spleen cells were incubated with B220 microbeads and enriched by magnetic cell sorting for B cells according to the manufacturer's instructions (Miltenyi Biotech) and used for immunoblot or real-time PCR analysis.
RNA Preparation and Analyses
RNA was prepared from cultured MEFs, magneticactivated cell sorting-sorted B cells, or lymphomas using the RNeasy kit (Qiagen). For real-time PCR, cDNA was prepared from 1 μg RNA using the iScript cDNA Synthesis kit (Bio-Rad). Real-time PCR was done using an iCycler machine (Bio-Rad) and the iTaq SYBR Green kit (Bio-Rad). Data analyses were done by comparing C t values with a control sample set as 1. Sequences for primers are available on request.
Immunoblotting
Protein extracts (20 or 50 μg per lane) were separated electrophoretically on a SDS-PAGE gel, transferred to membranes (Protran, Schleicher & Schuell), and blotted with antibodies specific for Skp2 (Zymed Laboratories, Inc.), p27
Kip1 (BD Biosciences Transduction Laboratories), c-Myc and E2f1 (Santa Cruz Biotechnology), and β-actin (Sigma Chemicals).
Statistical Analyses
The statistical analysis of survival differences in Eμ-Myc transgenics of Skp2 −/− versus Skp2 +/+ genotype was done using a Cox regression analysis with a multiple cohort comparison Bonferroni adjusted. The statistics done to analyze differences in the ex vivo and in vivo B-cell proliferation and apoptosis indices involved paired t tests.
Results
Myc Induces Skp2 Expression
Myc suppresses p27 Kip1 expression primarily by provoking ubiquitin-mediated destruction of p27
Kip1 protein (8) . Mechanistically, this occurs through Myc-mediated induction of upstream activators of the cyclin E-Cdk2-p27 Kip1 pathway such as E2f1 (34) and of the Cul1 and Cks1 components of the SCF Skp2 complex that directs p27 Kip1 degradation (31, 39) . Specifically, Cks1 levels are markedly elevated in the premalignant B cells of Eμ-Myc transgenic mice, whereas the expression of the Skp1, Rbx1, and Cul1 components of the SCF Skp2 complex is similar to those expressed in B cells from wild-type littermates (31) . However, the expression of the Skp2 F-box protein that binds to phospho-p27
Kip1 is also elevated in precancerous Eμ-Myc B cells ( Fig. 1A and B) . Furthermore, Skp2 levels are also markedly elevated in lymphomas that arise in Eμ-Myc mice ( Fig. 1C ; ref. 31 ) and in human Burkitt lymphoma, where 12 of 14 Burkitt lymphoma samples analyzed expressed elevated levels of Skp2 mRNA and protein compared with control B cells ( Fig. 1D and E). Increased levels of Skp2 were not due to Skp2 amplification as previously noted in lung cancers (43) , as assessed by Southern blot analyses of Eμ-Myc lymphomas (data not shown). Thus, Skp2 expression is augmented by Myc in vivo, and high levels of Skp2 are a hallmark of Myc-driven lymphoma.
To determine if Skp2 is also induced by Myc in other cell contexts, wild-type MEFs were infected with an MSCV-based retrovirus encoding the conditional Myc-ER TAM transgene and the puromycin resistance (Puro R ) gene (44) . As a control, MEFs were infected with a retrovirus only expressing the Puro R gene. Puromycin-resistant cells were expanded in culture and then treated with the estrogen receptor (ER) agonist 4-HT, which selectively activates Myc-ER TAM . As expected, Myc activation led to the induction of the direct Myc target gene Ornithine decarboxylase (Odc; ref. 45) and also led to the induction of Skp2, although the magnitude of the Skp2 response was not as robust ( Fig. 2A) .
Myc activates the majority of its transcription targets by binding, in conjunction with its requisite dimerization partner Max, to E-box elements harboring CACGTG or CACATG recognition elements (46, 47) . The mouse (and human) Skp2 promoter-regulatory regions lack such sites, suggesting that Myc might regulate Skp2 expression in an indirect fashion. To address this issue, Myc-ER TAM -expressing MEFs were pretreated (for 30 minutes) with cycloheximide to block de novo protein synthesis. Activation of Myc-ER TAM failed to induce Skp2 mRNA in the presence of cycloheximide, whereas p27
Kip1 transcripts were still suppressed (Fig. 2B) . To assess the possibility that elevated Myc levels affect the half-life of Skp2 transcript or protein, we analyzed Myc-expressing earlypassage MEFs that were treated with actinomycin D, which blocks RNA synthesis or cycloheximide to block de novo protein synthesis. No increase in RNA half-life was detected (Supplementary Fig. S1A ), whereas Skp2 protein half-life was significantly prolonged on ectopic Myc expression (Fig. 2C) . Therefore, the regulation of Skp2 by Myc is indirect and involves transcriptional as well as posttranslational mechanisms.
Skp2 Induction by Myc Is Independent of E2f1
E2f1 (Supplementary Fig. S1B ; ref. 35) . Furthermore, Skp2 promoter activity was significantly induced following cotransfection of an E2f1 expression plasmid ( Supplementary Fig. S1C ). Thus, we predicted that Myc would induce Skp2 via the agency of E2f1 and tested this hypothesis by evaluating the expression of Skp2 in the precancerous B220 + B cells of Eμ-Myc;E2f1 +/+ versus Eμ-Myc;E2f1 −/− littermates. As expected, E2f1 transcripts were elevated in precancerous Eμ-Myc B cells (34) , and Skp2 mRNA levels were elevated 3-to 4-fold in Eμ-Myc B cells compared with levels expressed in the B cells of nontransgenic littermates. Surprisingly, similarly increased levels of Skp2 transcripts were evident in Eμ-Myc;E2f1 −/− B cells (Fig. 3A) ; thus, the induction of Skp2 expression by Myc, at least in this cell context, is E2f1 independent. Furthermore, the lymphomas that arose in Eμ-Myc;E2f1 −/− mice actually expressed somewhat higher levels of Skp2 protein than those expressed in Eμ-Myc;E2f1 +/+ lymphomas (data not shown). Finally, Skp2 protein levels were similarly elevated in E2f1 +/+ versus E2f1 −/− MEFs transduced with MSCV-Myc-IRES-GFP retrovirus (Fig. 3B) . Therefore, the induction of Skp2 by Myc is E2f1 independent.
Loss of Skp2 Does Not Significantly Delay MycInduced Lymphoma Onset
Cks1 loss triples the life span of Eμ-Myc transgenics (31). The markedly increased levels of Skp2 in Eμ-Myc transgenic B cells and Myc-driven lymphomas (Fig. 1) suggested that Skp2 might also play critical roles in Myc-induced tumorigenesis. To test this hypothesis, we initially coexpressed Skp2 or Cks1 with Myc in immortalized BALB/c-3T3 fibroblasts. However, there were no appreciable effects of enforced expression of either Skp2 or Cks1 on Myc-induced colony formation in soft agar ( Supplementary Fig. S2A-C) .
To directly assess the role of Skp2 in Myc-induced tumorigenesis, Eμ-Myc transgenics (C57BL/6) were mated to Skp2 −/− mice (17) and Eμ-Myc;Skp2 +/− F1 offspring were bred to Skp2 +/− mice to obtain the desired Eμ-Myc; Skp2 +/+ , Eμ-Myc;Skp2 +/− , and Eμ-Myc;Skp2 −/− cohort. These littermates were followed for lymphoma onset, and 4-week-old mice were assessed for hallmarks of the precancerous phase of the disease, including lymphocytosis and splenomegaly. WBC numbers and spleen weights of Skp2 −/− mice were similar to those of Skp2 +/+ littermates (data not shown). As expected, Eμ-Myc;Skp2 +/+ mice showed elevated numbers of WBC and lymphocytes, as well as obvious splenomegaly. Notably, there were moderate reductions in total WBC numbers in Skp2-null Eμ-Myc;Skp2 −/− cohorts; Fig. 4A , right). There were essentially no effects of Skp2 heterozygosity on these parameters (data not shown). Therefore, loss of Skp2 moderately attenuates the precancerous phase of disease in Eμ-Myc transgenic mice.
The premalignant B220 + B cells of Eμ-Myc transgenics have high proliferative indices, but this response is counterbalanced by the activation of apoptotic checkpoints in these cells (29, 34) . There was no difference in the apoptotic indices of precancerous B220 + Eμ-Myc;Skp2 +/+ and Eμ-Myc;Skp2 −/− B cells in vivo by Annexin V + fluorescence-activated cell sorting (FACS) analyses (data not shown). Further, the apoptotic indices of Eμ-Myc;Skp2
and Eμ-Myc;Skp2 −/− B cells cultured ex vivo in medium supplemented with interleukin-7 were similar (Fig. 4B) . Loss of Cks1 markedly impairs the hyperproliferative response of Eμ-Myc B cells (31) . Thus, we predicted that Skp2 loss would similarly affect the proliferative response of Myc. Indeed, Skp2-deficient Eμ-Myc B cells had significantly slower growth indices than B cells derived from the bone marrow of their wild-type transgenic littermates when cultured ex vivo (Fig. 4C) . However, these differences were not manifest in vivo, where the proliferative indices of Eμ-Myc;Skp2 +/+ and Eμ-Myc;Skp2 −/− B220 + B cells were similar (Fig. 4D) . Therefore, unlike Cks1 (31), Skp2 does not contribute to the proliferative response of Myc in B cells in vivo.
Eμ-Myc transgenic mice succumb to aggressive, disseminating pre-B/immature B-cell lymphoma, generally within 4 months of age (41) . Quite remarkably, Cks1 loss nearly triples the life span of Eμ-Myc mice (31) . Nontransgenic littermates lacking Skp2 showed no signs of tumor development throughout their life span. Surprisingly, Eμ-Myc; Skp2 −/− transgenic mice showed an only moderately delayed course of lymphoma development, with a median survival of 143 days compared with median survival of 97 days of their Eμ-Myc;Skp2 +/+ littermates (P = 0.405, not significant; Fig. 5 ). There was no effect of Skp2 heterozygozity on survival (median survival of 95 days; Fig. 5 ). The lymphomas that arose in Skp2-null Eμ-Myc transgenics were phenotypically identical (pre-B and immature B-cell lymphomas) to those that arose in wild-type Eμ-Myc transgenic littermates (data not shown). Thus, in sharp contrast to Cks1 loss, Skp2 loss has very moderate, statistically nonsignificant effects on Myc-driven lymphomagenesis.
Skp2 Loss Abolishes the Ability of Myc to Suppress p27 Kip1
Given the ability of Myc to induce Skp2 expression while repressing p27
Kip1 protein levels (Fig. 1) , and the well-established role of the SCF Skp2 complex in directing p27
Kip1 degradation (12, 17) , we evaluated p27 Kip1 RNA and protein levels in splenic B220 + B cells from precancerous Eμ-Myc;Skp2 +/+ and Eμ-Myc;Skp2 −/− littermates. littermates were injected with bromodeoxyuridine, and cells from bone marrow and spleen were harvested after 12 h. Bromodeoxyuridine incorporation was then determined by FACS. Columns, mean of three independent experiments; bars, SE. The differences between Eμ-Myc;Skp2 +/+ and Eμ-Myc;Skp2
Notably, the ability of Myc to suppress p27 Kip1 protein levels was essentially cancelled in Skp2-deficient Eμ-Myc B cells, both in vivo (Fig. 6A) and ex vivo (Fig. 6B) . By contrast, p27
Kip1 mRNA was suppressed in all Eμ-Myc B cells, regardless of their Skp2 status (Fig. 6C) . Thus, like Cks1 (31), Skp2 is specifically required for Myc-mediated downregulation of p27 Kip1 protein levels. Finally, unlike lymphomas that arose in Eμ-Myc;Skp2
littermates, nearly all Eμ-Myc;Skp2 −/− lymphomas maintained high levels of p27 Kip1 protein expression (data not shown).
Skp2 has been suggested to regulate Myc ubiquitination and stability and to function as an essential coactivator of Myc-mediated transactivation (51, 52) . If Skp2 were to play essentials role in regulating Myc protein levels, a prediction was that Myc protein levels would be elevated in Skp2-deficient Eμ-Myc transgenic B cells. This was clearly not the case, as Skp2 loss had essentially no effect on the steady-state levels of Myc protein in Eμ-Myc transgenic B cells, either in vivo or ex vivo ( Fig. 6A and B) . We also addressed if Skp2 affected the transcriptional activity of Myc analyzing the expression of the established Myc target genes Cad (53) and Rcl (54) in precancerous B220 + B cells from Eμ-Myc;Skp2
+/+ versus Eμ-Myc;Skp2 −/− littermates. There were essentially no changes in the levels of Rcl transcript in this cohort, and, if anything, the levels of Cad mRNA were elevated by Skp2 heterozygosity or loss (Supplementary Fig. S3) . Therefore, at least the induction of these two bona fide transcription targets of Myc is independent of Skp2.
Discussion
Myc promotes cell cycle entry and accelerates the rates of proliferation by suppressing the levels of p27
Kip1 , a key cell cycle inhibitor (31, 34, 40) . The SCF Skp2 allosteric regulator Cks1 is a target induced by Myc that clearly plays major roles in the proliferative response of Myc and in Myc-driven tumorigenesis in the Eμ-Myc transgenic mouse model of human B-cell lymphoma. Further, Cks1 overexpression is a hallmark of Myc-driven lymphomas in mouse and man, and is absolutely required for Myc to suppress p27
Kip1 protein levels in vivo (31 Skp2 was revealed, as predicted, to be essential for Mycmediated suppression of p27
Kip1 levels in Eμ-Myc B cells. These findings, along with those showing that p27
Kip1 deficiency accelerates lymphoma onset in Eμ-Myc transgenics (40) and that Cks1 loss impairs Myc-induced proliferation and lymphomagenesis (31) , strongly suggested that Skp2 loss would cancel the proliferative response of Myc and thus impair Myc-induced lymphoma development. Surprisingly, this was not the case, where despite fully restoring p27
Kip1 levels the effects of Skp2 loss on Myc-induced proliferation and lymphoma development were at most moderate compared with those manifest in the Cks1 deficiency (31) . These findings suggest that at least in this context Cks1 has functions other than that as a regulator of p27
Kip1 that also contribute to Myc-induced proliferation and tumorigenesis. Indeed, Cks1 has functions as a regulator of transcription in yeast (55, 56) and human cancer cells (57) and seems to have Skp2/p27
Kip1 -independent functions in controlling human multiple myeloma cell growth and survival (58) .
The importance of Skp2 in cancer has be documented, where Skp2 expression is highly elevated in several malignancies and where this is associated with reduced p27 Kip1 levels, high proliferative rates, and poor outcome (15, 59) . Furthermore, Skp2 cooperates with oncogenic N-Ras in promoting anchorage-independent growth of rodent fibroblasts in vitro and in promoting lymphomagenesis in vivo (48) . In contrast, Skp2 does not augment Myc-induced soft agar growth of fibroblasts ( Supplementary Fig. S2 ), and Skp2 loss has no significant effects on Myc-driven lymphomagenesis despite canceling the ability of Myc to suppress p27 Kip1 protein levels. We conclude that there are context-specific effects of Skp2 in tumorigenesis.
Myc oncoproteins are short-lived, and Myc turnover occurs through the ubiquitin-proteasome pathway (60) . Skp2 has been suggested to bind to c-Myc, to promote its ubiquitination and degradation, and to also augment its transactivation functions (51, 52) . If this scenario were operational in B cells, then Skp2 loss should have at least led to increased levels of Myc protein in Eμ-Myc B cells and thus perhaps to accelerated disease, as homozygous Eμ-Myc transgenics develop more rapid lymphomas than hemizygous Eμ-Myc littermates (61) . Neither of these responses was, however, evident in Eμ-Myc;Skp2 −/− mice, and the expression of at least some established Myc targets was also unaffected in Skp2-deficient Eμ-Myc B cells. Our findings are thus more in accord with those of others indicating that the F-box protein Fbw7 (20, 62) or HectH9 (63) regulates Myc turnover.
In normal cells, the ability of Myc to accelerate proliferation is harnessed by the activation of apoptotic pathways, and disabling this response, by loss-of-function mutations in the Arf-p53 tumor suppressor pathway (29) , dramatically accelerates the course of Myc-induced malignancies. The effects of biallelic loss of p27
Kip1 on lymphoma onset in Eμ-Myc mice are less dramatic (40) , yet the Skp2/Cks1-p27 Kip1 pathway is affected in all Myc-driven lymphomas (this report and ref. 31 ). Myc-mediated induction of Skp2 is indirect, suggesting that Myc may work through the agency of other transcription factors to induce Skp2. One candidate was E2f1, as Myc induces E2f1 and because E2f1 is required for Myc-mediated repression of p27
Kip1 in Eμ-Myc B cells (34) . Further, in immortal fibroblasts and some tumor cell lines, E2f1 promotes p27
Kip1 degradation via its induction of Skp2 (49), and in pancreatic cancer, the malignant phenotype is associated with E2f1-dependent induction of Skp2 (64) . The finding that Myc-induced expression of Skp2 is independent of E2f1 was thus surprising, and a role for FoxM1, another activator of Skp2 transcription (65), seems also unlikely, as FoxM1 expression is reduced in Eμ-Myc B cells and lymphomas (31) . Thus, other transcriptional regulators downstream of Myc must control Skp2 expression. The complexity of Skp2 regulation is further documented by an increase in Skp2 protein half-life that points to posttranslational effects of Myc. The fact that the effects of Skp2 loss on Myc-induced lymphomagenesis are moderate at best, however, strongly points toward Cks1 roles besides SCF Skp2 and p27 Kip1 control.
Skp2 overexpression in cancer has heretofore been linked to SKP2 gene amplification, E2f1, and FoxM1. Our findings strongly suggest that Myc regulates Skp2 expression to control p27 Kip1 levels. The effect of Skp2 loss on Myc-driven proliferation and lymphomagenesis was surprisingly modest. Given differences in the magnitude of the effects of Cks1 versus Skp2 loss on Myc-mediated tumorigenesis suggest other Cks1 targets (e.g., not linked to SCF Skp2 ) that can be exploited in cancer therapeutics.
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